Ovarian Cancer Precision Diagnosis
At Fosun Health, ovarian cancer diagnosis is not just about “finding a mass”—it is about understanding the tumor’s origin, spread, and genetic vulnerabilities to design a plan that preserves your fertility, your body image, and your future. Our streamlined pathway delivers answers within days:
We use a multimodal approach tailored to the pelvis and abdomen:
- Transvaginal Ultrasound (TVUS): The first-line tool to visualize the ovaries, detect masses, and characterize cysts as benign or suspicious.
- Contrast-Enhanced CT (Abdomen & Pelvis): Evaluates the extent of disease, peritoneal spread, lymph nodes, and liver/lung metastases.
- Pelvic MRI: Provides superior soft-tissue resolution to distinguish between benign and malignant ovarian tumors, and assess local invasion.
- CA125 & HE4: Combined with imaging, these biomarkers improve diagnostic accuracy.
- The ROMA index (Risk of Ovarian Malignancy Algorithm): Helps stratify risk.
- Liquid Biopsy: A simple blood draw can detect circulating tumor DNA when tissue biopsy is challenging.
- Ultrasound-Guided Biopsy: For suspected metastatic or recurrent disease, we obtain tissue with minimal discomfort.
- Diagnostic Laparoscopy: In select cases, we use minimally invasive surgery to visualize and biopsy peritoneal spread.
- PET-CT: Detects distant metastases (liver, lungs, distant lymph nodes) and extra-abdominal spread.
- Diagnostic Laparoscopy with Peritoneal Washing: Essential for accurate staging of early ovarian cancer.
Using NGS (Next-Generation Sequencing), we analyze BRCA1/2, HRD (Homologous Recombination Deficiency) score, HER2, MSI/dMMR, TMB, NTRK fusions, and over 300 cancer-related genes. This determines whether your tumor will respond to PARP inhibitors (olaparib, niraparib, fuzuloparib), anti-HER2 therapies, immunotherapy, or clinical trials of novel ADCs and bispecific antibodies—ensuring your treatment is matched to your tumor’s unique biology, not a generic protocol.
